Tag

#Biotech Layoffs

1 story

UAE & GCC · 9 hours ago

Enlivex Cuts 60% of Workforce, Scraps Preclinical R&D, and Slashes Executive Pay to Fund Osteoarthritis Trial

Enlivex slashes 60% of staff, halts preclinical R&D, and cuts executive pay by up to 40% to fund its Phase 2b knee osteoarthritis trial through mid-2027.

The Brief, in your inbox

Five must-reads.
Every Monday.

A curated digest of the week's biggest career, AI, and business stories. With our take. No spam.

Or subscribe via RSS · Protected by reCAPTCHA

We use essential cookies for login and preferences, and optional cookies for analytics. Privacy policy.

Enlivex Cuts 60% of Workforce, Scraps Preclinical R&D, and Slashes Executive Pay to Fund Osteoarthritis Trial

Five must-reads.Every Monday.

Log Out

Five must-reads.
Every Monday.